← board
ENZN
distress 4/10 · elevated risk$4.35-1%today-44% from 52w high
Revenue
$87M
Liquidity
$29M
Runway
1.5 yrs
Shares 1y
-81%
Price & events
+8600.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
+2.4%
1W
-19.4%
1M
-36.3%
3M
+8600.0%
6M
+4733.3%
1Y
+2800.0%
2Y
+625.0%
5Y
+1573.1%
All
Overview
- Market Cap
- $62.34M
- Enterprise Value
- $113.45M
- Volume
- 2.30K
- 52 Week Range
- $0.03 – $7.80
- Total Shares
- 14.33M
- Float Shares
- 14.31M
- % Held by Insiders
- 0.68%
- % Held by Institutions
- 94.73%
- RVOL
- 1.60x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.